After it was approved in 2019, Spravato, a depression treatment derived from the club drug ketamine, was looking like a dud. But recently it has taken off, and it surpassed $1 billion in annual sales last year for its maker, Johnson and Johnson.

Further Listening: 
-<a href="https://open.spotify.com/episode/2ryZQQmOlB7wFQ5StLNWkA?si=6a1c406d92c341be">A Lawyer Says He Doesn't Need Help for Psychosis. His Family Disagrees.</a> 
-<a href="https://open.spotify.com/episode/6zM2k2m6ukUX7JJahmbYxs?si=417529a60ca54ca5">America's Maternal Mental Health Crisis</a> 

Further Reading: 
-<a href="https://www.wsj.com/health/healthcare/johnson-and-johnson-spravato-ketamine-drug-4ec21364?st=Vn8jdY">J&J’s Ketamine-Derived Drug Is Taking Off</a> 
-<a href="https://www.wsj.com/tech/biotech/big-pharma-walked-away-from-mental-health-why-some-are-coming-back-e2f1ec15">Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.</a> 

 Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices">megaphone.fm/adchoices</a>

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

The New Hit Depression Treatment? A Ketamine-Derived Nasal Spray

The Journal.

AI Chapters

AI Insights

Reviews